Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.36 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2253149 | 0.84 | SLC6A4 (0.41) | SLC6A4DAOALDH1A1MAOANPC1 | |
| SCHEMBL2256630 | 0.82 | DAO (0.54) | DAOALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2045757 | 0.81 | DAO (0.41) | DAOALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL2252606 | 0.81 | VKORC1 (0.40) | VKORC1SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL4663323 | 0.79 | PDE3B (0.45) | VKORC1DAOALDH1A1MAPTNPSR1 | |
| SCHEMBL2257130 | 0.79 | DAO (0.49) | DAOALDH1A1MAPTKMT2AHSD17B10 | |
| SCHEMBL2050121 | 0.78 | SLC5A2 (0.40) | VKORC1SLC6A4SLC6A2SLC6A3ALDH1A1 | |
| SCHEMBL2251990 | 0.78 | DAO (0.39) | DAOALDH1A1RAB9ANPSR1SLC5A1 | |
| SCHEMBL1267462 | 0.77 | PTGS2 (0.44) | VKORC1SLC6A4SLC6A2SLC6A3MAPT | |
| SCHEMBL2254318 | 0.77 | ERAP1 (0.51) | VKORC1DAOALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989424-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| EP-1354888-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL (JP) | 2009-05-20 | — | — | EP | disclosed |
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | KISSEI PHARMACEUTICAL CO. LTD. (JP) | 2009-04-09 | — | — | US | disclosed |
| EP-1364957-B1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2008-12-31 | — | — | EP | disclosed |
| US-7465713-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-12-16 | — | — | US | disclosed |
| US-7429568-B2 | Antidiabetic agents; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; hyperglycemia, obesity; 3-(6-O-ethoxycarbonyl- beta -D-glucopyranosyloxy)-4-[(4-isopropoxyphenyl)methyl]-1-isopropyl-5-methylpyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-09-30 | — | — | US | disclosed |
| US-7393838-B2 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-01 | — | — | US | disclosed |
| US-7189702-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-13 | — | — | US | disclosed |
| US-7115575-B2 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-7087579-B2 | Glucopyranosyloxypyrazole derivatives and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | KISSEI PHARMACEUTICAL CO., LTD. | 2004-07-29 | — | — | US | disclosed |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1432720-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | Bristol-Myers Squibb Company (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1213296-B1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1364957-A1 | GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
| EP-1354888-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | Kissei Pharmaceutical Co., Ltd. (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | BRISTOL-MYERS SQUIBB COMPANY | 2003-05-08 | — | — | US | disclosed |
| WO-2003020737-A1 | O-PYRAZOLE GLUCOSIDE SGLT2 INHIBITORS AND METHOD OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-03-13 | — | — | WO | disclosed |
| EP-1213296-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093419-A1 | GLUCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND USE THEREOF IN MEDICINES | SLC5A2, SLC5A1, SLC2A4 | VKORC1 1919/4885SLC6A4 146/4885SLC6A2 107/4885 |
| US-20040132669-A1 | Human sodium glucose co-transporter 2 (SGLT2) inhibitors; hypoglycemic agents, antidiabetic agents; obesity; prodrugs | SLC5A2, SLC5A1, SLC2A1 | VKORC1 2651/4885SLC6A4 82/4885SLC6A2 64/4885 |
| US-20030087843-A1 | O-pyrazole glucoside SGLT2 inhibitors and method of use | SLC5A2, SLC5A1, SLC2A1 | VKORC1 1777/4885SLC6A4 155/4885SLC6A2 460/4885 |
| US-20040063646-A1 | Glucopyranosyloxypyrazole derivatives and use thereof in medicines | SLC5A2, SLC5A1, UGGT1 | VKORC1 2081/4885SLC6A4 162/4885SLC6A2 117/4885 |
| US-20040147729-A1 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof | SLC5A1, SLC5A2, UGGT1 | VKORC1 1984/4885SLC6A4 197/4885SLC6A2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.